Cargando…

Two-year follow-up results after re-administration of etanercept in active ankylosing spondylitis

Detalles Bibliográficos
Autores principales:	Baraliakos, X, Brandt, J, Listing, J, Haibel, H, Rudwaleit, HM, Sieper, J, Braun, J
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2005
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2834027/ http://dx.doi.org/10.1186/ar1549

Ejemplares similares

Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumor necrosis factor alpha antibody infliximab
por: Baraliakos, X, et al.
Publicado: (2005)

Clinical response to discontinuation of anti-tumor necrosis factor therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab
por: Baraliakos, X, et al.
Publicado: (2005)

Clinical response to the anti-tumor necrosis factor alpha antibody infliximab in patients with ankylosing spondylitis over 3 years
por: Baraliakos, X, et al.
Publicado: (2005)

Long-term outcome of patients with active ankylosing spondylitis with etanercept-sustained efficacy and safety after seven years
por: Baraliakos, Xenofon, et al.
Publicado: (2013)

The relationship between inflammation and new bone formation in patients with ankylosing spondylitis
por: Baraliakos, Xenofon, et al.
Publicado: (2008)

Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab
por: Baraliakos, Xenofon, et al.
Publicado: (2005)

Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor alpha receptor fusion protein etanercept
por: Baraliakos, X, et al.
Publicado: (2005)

Correction: Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab
por: Baraliakos, Xenofon, et al.
Publicado: (2005)

Incorporation of the anteroposterior lumbar radiographs in the modified Stoke Ankylosing Spondylitis Spine Score improves detection of radiographic spinal progression in axial spondyloarthritis
por: Llop, Maria, et al.
Publicado: (2019)

Infertility improved by etanercept in ankylosing spondylitis
por: Rezvani, Aylin, et al.
Publicado: (2008)

Treatment of ankylosing spondylitis: focus on etanercept
por: Frech, Tracy
Publicado: (2007)

Non-radiographic axial spondyloarthritis and ankylosing spondylitis: what are the similarities and differences?
por: Baraliakos, X, et al.
Publicado: (2015)

Serum levels of leptin and high molecular weight adiponectin are inversely associated with radiographic spinal progression in patients with ankylosing spondylitis: results from the ENRADAS trial
por: Hartl, Agnes, et al.
Publicado: (2017)

Spinal radiographic progression over 2 years in ankylosing spondylitis patients treated with secukinumab: a historical cohort comparison
por: Braun, J., et al.
Publicado: (2019)

Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial
por: Song, I-H, et al.
Publicado: (2011)

Relevance of structural damage in the sacroiliac joints for the functional status and spinal mobility in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort
por: Protopopov, Mikhail, et al.
Publicado: (2017)

Inefficacy or Paradoxical Effect? Uveitis in Ankylosing Spondylitis Treated with Etanercept
por: Raffeiner, Bernd, et al.
Publicado: (2014)

Relapsing Polychondritis in a Patient with Ankylosing Spondylitis Using Etanercept
por: Azevedo, Valderilio Feijó, et al.
Publicado: (2014)

Long-term safety and efficacy of etanercept in the treatment of ankylosing spondylitis
por: Senabre-Gallego, José Miguel, et al.
Publicado: (2013)

Toll-like receptor 4 polymorphisms and ankylosing spondylitis
por: Adam, R, et al.
Publicado: (2005)

TNF-alpha antagonists for treatment of juvenile ankylosing spondylitis
por: Orbán, I, et al.
Publicado: (2011)

Intra-rater reliability of the bath ankylosing spondylitis disease activity index (BASDAI) and the bath ankylosing spondylitis functional index (BASFI) in children with spondyloarthritis
por: Batthish, Michelle, et al.
Publicado: (2012)

Fifty years after the discovery of the association of HLA B27 with ankylosing spondylitis
por: Braun, Juergen, et al.
Publicado: (2023)

Etanercept in the treatment of ankylosing spondylitis: A systematic review and meta-analysis
por: LIU, YA-FEI, et al.
Publicado: (2014)

Effects of etanercept and infliximab on bone metabolism indexes in patients with ankylosing spondylitis
por: Wang, Chenghai, et al.
Publicado: (2020)

Correlation of histopathological findings and magnetic resonance imaging in the spine of patients with ankylosing spondylitis
por: Appel, Heiner, et al.
Publicado: (2006)

Safety and Clinical Responses in Ankylosing Spondylitis after Three Months of Etanercept Therapy
por: Choi, Chan-Bum, et al.
Publicado: (2008)

Modified stoke ankylosing spondylitis spinal score as an outcome measure to assess the impact of treatment on structural progression in ankylosing spondylitis
por: van der Heijde, Désirée, et al.
Publicado: (2019)

New developments in ankylosing spondylitis—status in 2021
por: Klavdianou, Kalliopi, et al.
Publicado: (2021)

Long-term efficiency of infliximab in patients with ankylosing spondylitis: real life data confirm the potential for dose reduction
por: Baraliakos, X, et al.
Publicado: (2016)

Predicting the outcome of ankylosing spondylitis therapy
por: Vastesaeger, Nathan, et al.
Publicado: (2011)

Influence of a polymorphism IL1B gene in the response of rheumatoid arthritis and ankylosing spondylitis patients treated with infliximab
por: Morales-Lara, M J, et al.
Publicado: (2010)

2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis
por: Braun, J, et al.
Publicado: (2011)

Role of TRAILR1 and TNFR1A polymorphisms in the susceptibility and pharmacogenetics of rheumatoid arthritis and ankylosing spondylitis patients treated with infliximab
por: Morales-Lara, M J, et al.
Publicado: (2010)

Erratum to: New developments in Ankylosing spondylitis – Status in 2021
por: Klavdianou, Kalliopi, et al.
Publicado: (2022)

Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-α therapy and other novel approaches
por: Braun, Juergen, et al.
Publicado: (2002)

The impact of a 2-year Etanercept administration on growth of patients with juvenile idiopathic arthritis
por: Trachana, M, et al.
Publicado: (2011)

Etanercept discontinuation in a cohort of juvenile idiopathic arthritis patients: etanercept inefficacy but not intolerance is associated with oral corticosteroid use
por: Southwood, TR, et al.
Publicado: (2008)

Relationship between active inflammatory lesions in the spine and sacroiliac joints and new development of chronic lesions on whole-body MRI in early axial spondyloarthritis: results of the ESTHER trial at week 48
por: Song, I-H, et al.
Publicado: (2011)

Pustular eruption induced by etanercept in a patient with ankylosing spondylitis: a rare side effect
por: Kara, Asude, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_jegfs608skcmr17iivuk546k36